AC Immune SA - ACIU Forward P/S Multiple
The market split for AC Immune (ACIU) depends on the outcomes of new drug trials, which necessitates strict liquidity management. Changes in the projected P/S ratio reflect revenue expectations, where the value 8.70 describes the current level. The Swiss business relies on alliances with pharma behemoths, creating a diversified portfolio of antibodies and vaccines to combat degenerative brain pathologies, thereby minimizing patent risks.
Analytical breakdowns for AC Immune
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital AC Immune|ACIU - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio AC Immune|ACIU - Company Aggregate Debts|Debt to Book Capitalization Ratio AC Immune Inc|ACIU - Company Long-Term Indebtedness|Company Short-Term Debts AC Immune|Quick Liquidity Indicator acimmune.com
- financial results and valuation multiples details:
ACIU - Net Profit|Expected Profit AC Immune|ACIU - Company Value to Net Income|Future Price to Earnings AC Immune Corp|ACIU - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple AC Immune Inc|ACIU - Operating profit EBITDA|Net earnings per share (EPS TTM) AC Immune|ACIU - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months acimmune.com|ACIU - Earnings per share increase in current year|Earnings growth forecast for next year AC Immune
- total revenue and sales volume data:
Fundamental company analysis:ACIU (AC Immune SA)
To identify fundamental benchmarks in the financial reporting of AC Immune (ACIU), analyzing the ratio of market capitalization to expected sales is critical. The trend of future value relative to revenue allows for the filtering of market noise by assessing the biotech platform's valuation through the lens of projected income, which is particularly relevant given the long-term patent protections and stable advances from pharma behemoths that ensure the financial sustainability of Alzheimer's disease therapy development.
Competitor analysis for AC Immune
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACAD: Forward P/S Multiple|xenon-pharma.com (XENE) - Forward P/S Multiple|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Forward P/S Multiple CPRX|Market Cap to Expected Sales Ratio Denali Corp|Harmony Biosciences - Forward Price-to-Revenue Multiple|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|TRVI (Trevi Therapeutics Inc) - Market Cap to Projected Revenue|PRAX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Anavex Life Sciences Corp (AVXL)|Forward Price-to-Revenue Multiple CBLL|Forward P/S Multiple Prothena Corporation|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|ANNX (Annexon Biosciences) - Forward Price to Sales|Price-to-Projected Revenue Ratio Omeros OMER|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|Voyager Therapeutics - Forward P/S Multiple|NMRA - Forward P/S Multiple|SCLX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Tevogen Bio Holdings Inc.|Forward Price-to-Revenue Multiple ACOG|CGTX: Forward Price to Sales|Forward P/S Multiple IKT|Market Cap to Expected Sales Ratio cassavasciences.com|Price-to-Projected Revenue Ratio Assertio ASRT|COYA - Forward Price-to-Revenue Multiple|VTGN - Price-to-Projected Revenue Ratio|Ovid Therapeutics Inc. (OVID) - Forward Price-to-Revenue Multiple|ABOS (Acumen Pharmaceuticals) - Forward Price-to-Revenue Multiple|cervomed.com (CRVO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|Market Cap to Projected Revenue CLNN (Clene Nanomedicine)|Forward P/S Multiple PEPG|JUNS - Market Cap to Future Revenue Ratio|Forward P/S Multiple RLMD (Relmada Therapeutics)|Forward P/S Multiple annovisbio.com ANVS|Grace Tx - Forward P/S Multiple|Firefly Neuroscience, Inc. (AIFF) - Forward Price-to-Revenue Multiple|KLTO: Forward P/S Multiple|NRSN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple RVPH|Forward P/S Multiple MetaVia, Inc.|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|heliusmedical.com - Market Cap to Projected Revenue|Forward P/S Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Future Revenue Ratio|NERV: Forward Price-to-Revenue Multiple|ATHA - Forward P/S Multiple|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|Alzamend Neuro - Forward Price to Sales|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Future Revenue Ratio Protagenic PTIX|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|BCLI - Forward Price-to-Revenue Multiple|CARA: Forward Price-to-Revenue Multiple|Forward Price to Sales CHRO (Chromocell)|ELYM: Forward P/S Multiple|ITCI - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple Marinus Pharmaceuticals Inc (MRNS)|Price-to-Projected Revenue Ratio NKGen (NKGN)|Forward Price-to-Revenue Multiple NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple synaptogen.com SNPX|TRVN - Price-to-Projected Revenue Ratio|VIGL (Vigil Neuroscience) - Market Cap to Projected Revenue|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
